1. Home
  2. GRNT vs MNPR Comparison

GRNT vs MNPR Comparison

Compare GRNT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Ridge Resources Inc.

GRNT

Granite Ridge Resources Inc.

HOLD

Current Price

$5.03

Market Cap

610.7M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$114.16

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNT
MNPR
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
610.7M
587.4M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
GRNT
MNPR
Price
$5.03
$114.16
Analyst Decision
Hold
Strong Buy
Analyst Count
1
11
Target Price
$6.00
$107.00
AVG Volume (30 Days)
800.2K
230.4K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
7.36%
N/A
EPS Growth
28.57
54.99
EPS
N/A
N/A
Revenue
$450,306,000.00
N/A
Revenue This Year
$18.12
N/A
Revenue Next Year
$13.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.49
N/A
52 Week Low
$4.18
$32.77
52 Week High
$6.15
$124.82

Technical Indicators

Market Signals
Indicator
GRNT
MNPR
Relative Strength Index (RSI) 54.28 53.18
Support Level $4.83 $102.88
Resistance Level $5.05 $114.60
Average True Range (ATR) 0.14 6.75
MACD -0.02 -1.31
Stochastic Oscillator 28.13 46.44

Price Performance

Historical Comparison
GRNT
MNPR

About GRNT Granite Ridge Resources Inc.

Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: